Deutetrabenazine: A Review in Chorea Associated with Huntington’s Disease

摘要

Abstract Oral deutetrabenazine (Austedo?), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms associated with Huntington’s disease (HD). In the pivotal 12-week phase III FIRST-HD trial ( n ?=?90), deutetrabenazine, at doses titrated for optimal chorea control and tolerability (maintenance dosage range 12–48 mg/day), was significantly more effective for controlling chorea in HD patients than placebo. In the ongoing phase III ARC-HD trial, a preliminary analysis demonstrated that deutetrabenazine treatment was associated with improvements in chorea control at 54?weeks in patients who had completed FIRST-HD (i.e. ≤?66?weeks’ treatment; rollover cohort) or switched overnight from tetrabenazine to deutetrabenazine. The tolerability profile of deutetrabenazine is similar to that of placebo, with most treatment-emergent adverse events of mild or moderate severity. In both trials, with the exception of somnolence, individual neuropsychiatric adverse events typically occurred in